

**Table 14-2.01**  
**Summary of Demographic and Baseline Characteristics**

		Placebo	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
		(N=86)				
Age (y)	n	86	84	84	254	0.5934
	Mean	75.2	75.7	74.4	75.1	
	SD	8.59	8.29	7.89	8.25	
	Median	76.0	77.5	76.0	77.0	
	Min	52.0	51.0	56.0	51.0	
	Max	89.0	88.0	88.0	89.0	
	<65 yrs	14 ( 16%)	8 ( 10%)	11 ( 13%)	33 ( 13%)	0.1439
	65-80 yrs	42 ( 49%)	47 ( 56%)	55 ( 65%)	144 ( 57%)	
	>80 yrs	30 ( 35%)	29 ( 35%)	18 ( 21%)	77 ( 30%)	
Sex	n	86	84	84	254	0.1409
	Male	33 ( 38%)	34 ( 40%)	44 ( 52%)	111 ( 44%)	
	Female	53 ( 62%)	50 ( 60%)	40 ( 48%)	143 ( 56%)	
Race (Origin)	n	86	84	84	254	0.6477
	Caucasian	75 ( 87%)	72 ( 86%)	71 ( 85%)	218 ( 86%)	
	African Descent	8 ( 9%)	6 ( 7%)	9 ( 11%)	23 ( 9%)	
	Hispanic	3 ( 3%)	6 ( 7%)	3 ( 4%)	12 ( 5%)	
	Other	0	0	1 ( 1%)	1 ( <1%)	
MMSE	n	86	84	84	254	0.5947
	Mean	18.0	17.9	18.5	18.1	
	SD	4.27	4.22	4.16	4.21	
	Median	19.5	18.0	20.0	19.0	

[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-square test for categorical variables.

NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first definite symptoms of Alzheimer's disease.

Source: C:\cdisc\_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas

21:02 Monday, June 26, 2006

**Table 14-2.01**  
**Summary of Demographic and Baseline Characteristics**

		Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
	Min	10.0	10.0	10.0	10.0	
	Max	23.0	24.0	24.0	24.0	
Duration of disease	n	86	84	84	254	0.1530
	Mean	42.7	48.7	40.5	43.9	
	SD	30.24	29.58	24.69	28.40	
	Median	35.3	40.3	36.0	36.3	
	Min	7.2	7.8	2.2	2.2	
	Max	183.1	130.8	135.0	183.1	
	<12 months	5 ( 6%)	3 ( 4%)	4 ( 5%)	12 ( 5%)	0.7885
	=>12 months	81 ( 94%)	81 ( 96%)	80 ( 95%)	242 ( 95%)	
Years of education	n	86	84	84	254	0.3875
	Mean	12.6	13.2	12.5	12.8	
	SD	2.95	4.15	2.92	3.38	
	Median	12.0	12.0	12.0	12.0	
	Min	6.0	3.0	6.0	3.0	
	Max	21.0	24.0	20.0	24.0	
Baseline weight (kg)	n	86	83	84	253	0.0030
	Mean	62.8	67.3	70.0	66.6	
	SD	12.77	14.12	14.65	14.13	
	Median	60.6	64.9	69.2	66.7	
	Min	34.0	45.4	41.7	34.0	
	Max	86.2	106.1	108.0	108.0	

[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-square test for categorical variables.

NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first definite symptoms of Alzheimer's disease.

Source: C:\cdisc\_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas

21:02 Monday, June 26, 2006

**Table 14-2.01**  
**Summary of Demographic and Baseline Characteristics**

		Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
Baseline height (cm)	n	86	84	84	254	0.1262
	Mean	162.6	163.4	165.8	163.9	
	SD	11.52	10.42	10.13	10.76	
	Median	162.6	162.6	165.1	162.9	
	Min	137.2	135.9	146.1	135.9	
	Max	185.4	195.6	190.5	195.6	
Baseline BMI	n	86	83	84	253	0.0133
	Mean	23.6	25.1	25.3	24.7	
	SD	3.67	4.27	4.16	4.09	
	Median	23.4	24.3	24.8	24.2	
	Min	15.1	17.7	13.7	13.7	
	Max	33.3	40.1	34.5	40.1	
	<25	59 ( 69%)	47 ( 56%)	44 ( 52%)	150 ( 59%)	0.2326
	25-<30	21 ( 24%)	27 ( 32%)	28 ( 33%)	76 ( 30%)	
	=>30	6 ( 7%)	10 ( 12%)	12 ( 14%)	28 ( 11%)	

[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-square test for categorical variables.

NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first definite symptoms of Alzheimer's disease.

Source: C:\cdisc\_pilot\PROGRAMS\DR AFT\TFLs\ads13.sas

21:02 Monday, June 26, 2006